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Background: Nephrotoxicity is the major side effect in cisplatin chemotherapy. Previously, we reported that
the ginsenosides Rk3 and Rh4 reduced cisplatin toxicity on porcine renal proximal epithelial tubular cells
(LLC-PK1). Here, we aimed to evaluate the protective effect of ginsenosides Rk3 and Rh4 on kidney function
andelucidate their antioxidant effect using in vitro and in vivomodels of cisplatin-induced acute renal failure.
Methods: An enriched mixture of ginsenosides Rk3 and Rh4 (KG-KH; 49.3% and 43.1%, respectively) was
puriﬁed from sun ginseng (heat processed Panax ginseng). Cytotoxicity was induced by treatment of
20mM cisplatin to LLC-PK1 cells and rat model of acute renal failure was generated by single intraperi-
toneal injection of 5 mg/kg cisplatin. Protective effects were assessed by determining cell viability,
reactive oxygen species generation, blood urea nitrogen, serum creatinine, antioxidant enzyme activity,
and histopathological examination.
Results: The in vitro assay demonstrated that KG-KH (50 mg/mL) signiﬁcantly increased cell viability (4.6-
fold), superoxide dismutase activity (2.8-fold), and glutathione reductase activity (1.5-fold), but reduced
reactive oxygen species generation (56%) compared to cisplatin control cells. KG-KH (6 mg/kg, per os) also
signiﬁcantly inhibited renal edema (87% kidney index) and dysfunction (71.4% blood urea nitrogen, 67.4%
creatinine) compared to cisplatin control rats. Of note, KG-KH signiﬁcantly recovered the kidney levels of
catalase (1.2-fold) and superoxide dismutase (1.5-fold).
Conclusion: Considering the oxidative injury as an early trigger of cisplatin nephrotoxicity, our ﬁndings
suggest that ginsenosides Rk3 and Rh4 protect the kidney from cisplatin-induced oxidative injury and
help to recover renal function by restoring intrinsic antioxidant defenses.
Copyright  2016, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
cis-Diamminedichloroplatinum (II) (cisplatin) is a chemothera-
peutic agent that has been used against cancer of the bladder,
cervix, esophagus, head, neck, ovaries, and testes since it gained
approval from the United States Food and Drug Administration inl National University, 1 Gwanak-ro
t al., Protective effect of ginse
16), http://dx.doi.org/10.1016
ht  2016, The Korean Society of G
d/4.0/).1978 [1]. The main anticancer mechanism of cisplatin is the inhi-
bition of mitosis through DNA damage in rapidly dividing cells.
Upon gaining access into cells, cisplatin is converted to the aquated
form through replacement of labile chloride ligands by water
molecules [2]. This electrolytic conversion results in a positively
charged and highly reactive electrophilic product, thereby leading, Gwanak-gu, Seoul 08826, Republic of Korea.
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through interaction with cellular components such as the DNA,
mitochondria, and endoplasmic reticula [3,4].
Despite its chemotherapeutic effectiveness, cisplatin has severe
side effects such as vomiting, nausea, digestive-tract disorders,
ototoxicity, neurotoxicity, and nephrotoxicity. Cisplatin nephro-
toxicity is the main limiting factor restricting the use of cisplatin in
the clinics [2,3]. Cisplatin nephrotoxicity is a complexmultifactorial
process, including preferential accumulation in proximal tubular
cells, metabolic activation, oxidative injury, cell death, inﬂamma-
tory tissue damage, and renal failure [5]. Preferential uptake of
cisplatin takes place in renal proximal tubular cells through
transporter systems, including high-afﬁnity copper transporter 1
and organic cation transporter 2, which are highly expressed in
renal proximal tubular cells [6e9]. Metabolism of cisplatin to
nephrotoxin, so called metabolic activation, produces highly reac-
tive cisplatinethiol conjugates through enzymatic reactions by
glutathione transferase, g-glutamyl transpeptidase, and cysteine-S-
conjugate b-lyase [10e12]. Speciﬁc accumulation and metabolic
activation of cisplatin in renal tubular cells localizes cisplatin
toxicity to the renal tissue, thereby resulting in renal cell death,
inﬂammation, ﬁbrogenesis, and tissue remodeling [13]. These
processes together culminate in the loss of renal function, trig-
gering nephrotoxicity. Of note, glutathione (GSH) depletion and
reactive cisplatin-thiol conjugates found in initial stage of cisplatin
exposure lead to an imbalance in the cellular redox status and
triggers oxidative stress and cellular loss in renal tissue [14].
Therefore, cisplatin-induced oxidative injury is considered an early
event of cellular toxicity and has pivotal roles in the cisplatin-
induced nephrotoxicity.
Panax ginseng, commonly known as ginseng, is a medicinal
plant that has been used intensively in traditional herbal medi-
cine for more than 2,000 years, and it is now used as a tonic or
functional food to improve quality of life [15e18]. Ginseng is one
of the best-selling herbal medicines as well as a popular research
subject in many ﬁelds of life sciences. Bioactive constituents of
ginseng have been well-deﬁned including ginsenosides, poly-
saccharides, phenolics, ﬂavonoids, and polyacetylenes [19]. These
compounds are known to be responsible for most of the bene-
ﬁcial effects of ginseng, which has a broad range of protective or
therapeutic effects against many diseases [20,21]. In particular,
ginsenosides, the unique compounds in Panax species, have been
studied intensively as the active components of ginseng that
have anticancer, antidiabetic, and antioxidant effects [15,22,23].
Steaming of ginseng expands the chemical diversity of the gin-
senosides within it. Sun ginseng (SG) is a typical steamed root of
Panax ginseng that has a more diverse range of ginsenosides not
found in raw ginseng [24e26]. SG saponins exhibit various
beneﬁcial effects for chronic renal failure, endothelial progenitor
cells, and hippocampal neurogenesis [27e29]. They are used as
ingredients for many commercial products including functional
foods and cosmetics.
Previously, we reported that ginsenosides Rk3 and Rh4were the
principal components in SG responsible for the protective effects
reducing cisplatin-induced toxicity in LLC-PK1 cells [30]. Ginseno-
sides Rk3 and Rh4 are isomers that differ from each other in the
location of the double bond (D20e21 and D20e22, respectively).
Despite this minor structural difference, ginsenosides Rk3 and Rh4
showed similar efﬁcacy in reducing the cisplatin cytotoxicity [30].
In the present study, we aimed to evaluate the protective effects of
ginsenosides Rk3 and Rh4 on kidney function and elucidate the
antioxidant effects using in vitro and in vivo models of cisplatin-
induced acute kidney injury (AKI). We demonstrated that ginse-
nosides Rk3 and Rh4 are potential adjuvants for reducing cisplatin-
induced AKI.Please cite this article in press as: Baek S-H, et al., Protective effect of ginse
and in vivo, Journal of Ginseng Research (2016), http://dx.doi.org/10.10162. Materials and methods
2.1. Materials and reagents
Extract of SG was a generous gift from Ginseng Science Inc.
(Seoul, Korea). Silica gel (230e400mesh) was obtained fromMerck
(Darmstadt, Germany). Solvents for extraction and column chro-
matography were purchased from Duksan Pure Chemicals (Ansan,
Korea). Diaion HP-20 was obtained from Mitsubishi Chemical In-
dustries (Tokyo, Japan). Dulbecco’s Modiﬁed Eagle Medium sup-
plemented with Nutrient Mixture F-12 (DMEM/F-12), fetal bovine
serum, and antibiotics (10,000 units/mL of penicillin G and
10,000 mg/mL streptomycin sulfate) for LLC-PK1 culture were pur-
chased from Invitrogen (Carlsbad, CA, USA). For reactive oxygen
species (ROS) measurement, 20,70-dichloroﬂuorescin diacetate
(DCFH-DA) was obtained from Invitrogen. Diagnostic kits for
measurement of blood urea nitrogen (BUN) and creatinine were
purchased from Asan Pharmaceuticals (Seoul, Korea). Assay kits for
catalase, glutathione reductase, and superoxide dismutase was
purchased from Cayman (Ann Arbor, MI, USA). A Bradford Protein
Assay kit (Thermo Scientiﬁc, Rockford, IL, USA) was used for
determination of proteins in cell or kidney homogenates. Cisplatin,
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT), HPLC-grade solvents, and other reagents were pur-
chased from SigmaeAldrich (St Louis, MO, USA).
2.2. Preparation of an enriched mixture of ginsenosides Rk3 and
Rh4
Polar constituents in the extract of SG were removed by passing
through the Diaion HP-20 column and repeated washing with
water. The ginsenoside fraction bound to Diaion HP-20 resin was
recovered by elution with methanol and fractionated using silica
column chromatography following the method described by Park
et al [26]. An enriched mixture of ginsenosides Rk3 and Rh4 (KG-
KH) was prepared by preparative reverse phase-HPLC using C18
column as stationary phase and mixture of MeOH/water as mobile
phase.
2.3. Identiﬁcation and quantitation of ginsenosides Rk3 and Rh4 in
KG-KH
Ginsenosides Rk3 and Rh4 in KG-KH were identiﬁed and
quantitated by reverse phase-HPLC with an evaporative light
scattering detector (ELSD) following the method described by
Kwon et al [24]. Each in-house reference standard of ginsenosides
Rk3 and Rh4 was used for identiﬁcation and quantitation. Liquid
chromatographyeelectrospray ionizationemass spectrometry
(LCeESIeMS) was used to identify ginsenosides Rk3 and Rh4 by
measuringmolecular ion in negative-ionmode. Sample solutions of
KG-KH (0.5 mg/mL) and various concentrations of standards con-
taining ginsenosides Rk3 and Rh4were prepared by dissolvingwith
methanol. Samples and standards (20 mL each) were injected, and
analyzed using HPLCeELSD.
2.4. Cell culture, drug treatment, and cell viability assay
LLC-PK1 cells were obtained from the American Type Culture
Collection (Manassas, VA, USA). Cells were grown with DMEM/F12
medium supplemented with 10% fetal bovine serum and antibiotics
(100 units/mL of penicillin G and 100 mg/mL streptomycin) in a
humidiﬁed 5% CO2 incubator at 37C. LLC-PK1 cells were seeded in
appropriate culture plates at 2.0 104 cells/cm2 and incubated for 1
d before treatment. Cells were treated with 20mM of cisplatin with
or without KG-KH and incubated further for 24 h. At the end ofnosides Rk3 and Rh4 on cisplatin-induced acute kidney injury in vitro
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Fig. 1. Structure of ginsenosides and chromatogram of enriched mixture of ginsenosides Rk3 and Rh4 (KG-KH). Structures of (A) ginsenoside Rk3 and (B) ginsenoside Rh4. (C)
Chromatogram of KG-KH. Solution of KG-KH (0.5 mg/mL) was analyzed using HPLC coupled with an evaporative light scattering detector.
S.-H. Baek et al / Rh4 and Rk3 ameliorates AKI 3incubation, cell viability was measured by the MTT assay following
manufacturer protocols. Cell viability was expressed as the per-
centage to that in the normal group (vehicle only).
2.5. ROS measurement
Measurement of intracellular ROS was carried out using an ROS-
sensitive ﬂuorescence probe of DCFH-DA [31]. At the end of incuba-
tionwith cisplatin or KG-KH, cells were incubatedwith 20mMDCFH-
DA for 30 min at 37C and then washed with phosphate-buffered
saline (PBS). Cellular ﬂuorescence of DCF, the deacetylated and
oxidized product of DCFH-DA, in the presence of cellular ROS was
visualized using a ﬂuorescencemicroscope (Olympus, Tokyo, Japan).
For quantitation of ROS generation, ﬂow cytometric analyses were
carriedout. Labeled cellsweredetached,washed, and resuspended in
PBS. Green ﬂuorescence of DCF in cells was analyzed using a ﬂow
cytometer (FACScalibur; BD Bioscience, San Jose, CA, USA).
2.6. In vivo model of cisplatin-induced AKI and drug administration
All experimentswereperformed in accordancewith theNational
Institutes of Health and Kyung Hee University (Seoul, Korea) guides
for Laboratory Animals Care and Use and approved by the Institu-
tional Animal Care and Use Committee in the Kyung Hee Medical
Center, Kyung Hee University. Male SpragueeDawley rats (180e
220 g) were purchased from Samtako Biokorea (Seoul, Korea). An-
imals were housed in a room maintained under 12-h lightedark
conditions at 24  2C with free access to water and food. Animals
were used for experiment after several days of adaptation to theirPlease cite this article in press as: Baek S-H, et al., Protective effect of ginse
and in vivo, Journal of Ginseng Research (2016), http://dx.doi.org/10.1016surroundings. Four groups (6 rats per group) were designated with
random clustering to avoid intergroup differences in body weight.
AKI was induced by a single intraperitoneal injection of cisplatin
(5.0 mg/kg body weight). KG-KH was given via the oral route to
cisplatin-treated rats once daily for 5 d from the day of cisplatin
injection (2mg/kg or 6mg/kg). The normal and control groupswere
treated with physiological (0.9%) saline or cisplatin injection
without KG-KH, respectively. Normal and control rats were given
water (per os) without KG-KH by following the same treatment
schedule. Bodyweightwasmeasured eachdaybefore treatment. Six
days after cisplatin injection, blood samples were obtained by car-
diac puncture under light ether anesthesia. Rats were sacriﬁced
immediately by cervical dislocation. Serum was recovered imme-
diately by centrifugation (3,000g, 20 min, 4C). Serum levels of urea
nitrogen and creatinine were determined using commercial kits.
Simultaneously, kidneys were isolated quickly, washed with cold
saline, blotted on ﬁlter paper to remove excess saline, and weighed.
Thereafter, whole kidneys were dissected into small pieces and
homogenized in cold PBS. Aliquots of kidney homogenates were
used for the antioxidant enzyme activity assay.
2.7. Antioxidant enzyme activity assay
Cellular or renal levels of the antioxidant enzymes such as
catalase (CAT), glutathione reductase (GR), and superoxide dis-
mutase (SOD) were determined using commercial assay kits
(Cayman). Cell or tissue homogenates were prepared following
manufacturer protocols. GR activity was determined by measuring
the oxidation rate of NADPH to NADPþ. Total SOD activity wasnosides Rk3 and Rh4 on cisplatin-induced acute kidney injury in vitro
/j.jgr.2016.03.008
Fig. 2. Ginsenoside Rk3 and Rh4 extract (KG-KH) protects LLC-PK1 cells against
cisplatin cytotoxicity. LLC-PK1 cells were treated with cisplatin and/or KG-KH for 24 h.
Cell viability was measured using the MTT assay. Bar represents mean  standard error
of the mean (n ¼ 3). Signiﬁcant differences were determined by the Student t test
(###p < 0.001 compared with normal cells) or ANOVA (*p < 0.05, **p < 0.01 compared
with cisplatin control cells). C, cisplatin control cells. N, normal cells. Fig. 3. Ginsenoside Rk3 and Rh4 extract (KG-KH) restores cisplatin-induced reactive
oxygen species (ROS) generation in LLC-PK1 cells. LLC-PK1 cells were treated with
cisplatin (20mM) and/or KG-KH (50 mg/mL) for 24 h. ROS were determined using a ROS-
sensitive ﬂuorescence probe (20 ,70-dichloroﬂuorescin diacetate). (A) Stained cells were
visualized using a ﬂuorescence microscope. (B) Scale bar represents 50 mm. Quanti-
tation was achieved using a ﬂow cytometer. Bar represents mean  standard error of
the mean (n ¼ 3). Signiﬁcant difference was determined by the Student t test
(*p < 0.05, *** p < 0.001). C, cisplatin control cells; N, normal cells.
Fig. 4. Ginsenoside Rk3 and Rh4 extract (KG-KH) recovers the antioxidant enzyme
activity in cisplatin-treated LLC-PK1 cells. LLC-PK1 cells were treated with cisplatin
(20mM) and/or KG-KH (50 mg/mL) for 24 h. At the end of incubation, cells were har-
vested, and cell homogenates were prepared and used for assays. (A) Superoxide
dismutase (SOD) and (B) glutathione reductase (GR) activity was measured using a
commercial kit. Bar represents mean  standard error of the mean (n ¼ 3). Signiﬁcant
differences were determined by the Student t test (*p < 0.05, **p < 0.01, ***p < 0.001).
C, cisplatin control cells; N, normal cells.
J Ginseng Res 2016;-:1e74determined by measuring the dismutation rate of superoxide rad-
icals generated by xanthine oxidase and hypoxanthine. CAT activity
was determined by colorimetric detection of formaldehyde pro-
duced from methanol by catalase in the presence of hydrogen
peroxide. Separately, protein content in each sample was deter-
mined using the Bradford Protein Assay kit (Thermo Scientiﬁc).
Antioxidant enzyme activity was expressed as the activity/mg of
protein.
2.8. Histological examinations
Kidneys were ﬁxed in 4% paraformaldehyde, embedded in
parafﬁn, and then cut into 4-mm sections. Sections were stained
with hematoxylineeosin and analyzed under a light microscope
equipped with camera. Histology of kidney was evaluated by the
incidences of cell death, exfoliation and shallowing, inﬁltration, and
cast formation. Each pathological marker was scored from 0 to 5 on
the basis of the semiquantitative percentage of tissue damage.
Tissue injury score was expressed as the sum of all scores [32].
2.9. Statistical analyses
Data are from at least three independent experiments. Results
are represented as the mean and standard error of the mean. SAS
9.4 (SAS institute Inc., Cary, NC, USA) was used for statistical anal-
ysis. Statistical signiﬁcance was determined by one-way analysis of
variance (ANOVA, Duncan’s multiple range tests) or Student t test at
indicated p value.
3. Results
3.1. Identiﬁcation and quantitation of ginsenosides Rk3 and Rh4 in
KG-KH
The structure of ginsenosides Rk3 and Rh4 are represented in
Fig. 1A and 1B. Identiﬁcation and quantitation of ginsenosides Rk3
and Rh4 in KG-KH was assessed using HPLCeELSD and LCeESIeMS
(negative-ion mode) analyses with authentic standards of each
ginsenoside. Ginsenosides Rk3 and Rh4were themajor compounds
in KG-KH (Fig. 1C). KG-KH was a mixture of 49.3% of Rk3 and 43.1%
of Rh4 (w/w %). Separately, the molecular ions of Rk3 and Rh4 [(M-Please cite this article in press as: Baek S-H, et al., Protective effect of ginse
and in vivo, Journal of Ginseng Research (2016), http://dx.doi.org/10.1016H) e ¼ 619] were conﬁrmed using LCeESIeMS analyses (data not
shown). Thus, KG-KH was the enriched mixture of ginsenosides
Rk3 and Rh4 (total 92.4%, w/w).3.2. KG-KH reduces cisplatin-induced cytotoxicity in LLC-PK1 cells
To establish a noncytotoxic range, KG-KH was treated alone to
LLC-PK1 cells for 24 h and cell viability was measured. KG-KH did
not induce noticeable cell death or severe morphologic changes
in LLC-PK1 cells at  50 mg/mL (data not shown). KG-KH (1e
50 mg/mL) and/or cisplatin (20mM) were treated to LLC-PK1 cells
for 24 h, and cell viability was assessed using the MTT assay
(Fig. 2). Cisplatin induced signiﬁcant loss of cell viability as
compared to the normal cells (p < 0.01). Consistent with ournosides Rk3 and Rh4 on cisplatin-induced acute kidney injury in vitro
/j.jgr.2016.03.008
Table 1
Effects of ginsenoside Rk3 and Rh4 (KG-KH) on body weight, kidney weight, kidney index, blood urea nitrogen (BUN), and creatinine in cisplatin-injected rats
Body weight (g) Kidney weight (g) Kidney index1) BUN (mg/dL) Creatinine (mg/dL)
Normal 257.3  9.0 2.00  0.20 0.78  0.08 9.48  3.08 0.78  0.21
CP 2) 211.2  7.3# 2.59  0.13# 1.23  0.07# 47.07  6.76# 2.67  0.55#
CP þ KG-KH (2 mg/kg) 219.3  13.9 2.39  0.09** 1.09  0.04** 38.63  4.51* 1.95  0.36*
CP þ KG-KH (6 mg/kg) 215.7  17.1 2.29  0.07** 1.07  0.1** 33.60  4.68** 1.80  0.35**
Data are presented as mean  standard deviations (n ¼ 6).
1) Kidney index represents % ratio of kidney weight to body weight.
2) CP indicates cisplatin (5.0 mg/kg, i.p.). Statistically signiﬁcant differences were determined by t test (# p < 0.01 compared with normal group) or ANOVA (*p < 0.05;
**p < 0.01 compared with CP control group).
S.-H. Baek et al / Rh4 and Rk3 ameliorates AKI 5previous result, KG-KH signiﬁcantly reversed cisplatin-induced
loss of cell viability in a concentration-dependent manner as
compared to the cisplatin control cells (p < 0.01 or p < 0.05).
Protective effect was highest at 50 mg/mL of KG-KH. Next, we
tested the effect of KG-KH on cisplatin-induced oxidative injury
which is considered as an important factor in the progress of
cisplatin nephrotoxicity.3.3. KG-KH inhibits cisplatin-induced ROS generation in LLC-PK1
cells
ROS generation was assessed by ﬂuorescence microscope and
ﬂow cytometer using a ROS-sensitive ﬂuorescent probe (DCFH-DA).
Cisplatin induced a predominant increase in the number of green
positive cells compared with normal cells, suggesting that cisplatin
induced a noticeable increase of ROS generation in cells (Fig. 3A).
However, KG-KH reduced the number of green positive cells, sug-
gesting that KG-KH reversed cisplatin-induced ROS generation.
Quantitative results using a ﬂow cytometer were also consistent
with microscopy data (Fig. 3B). Cisplatin induced a signiﬁcant in-
crease in the number of green positive cells as compared to normal
cells (p < 0.001), but KG-KH signiﬁcantly inhibited the cisplatin-
induced increase in the number of green positive cells as
compared to cisplatin control cells (p < 0.05). These ﬁndings
implied that KG-KH restored cisplatin-induced oxidative damage in
terms of ROS production. Cellular ROS homeostasis is tightly
regulated by intracellular antioxidant enzymes, so next we exam-
ined the effect of KG-KH on the activity of antioxidant enzymes.Fig. 5. Ginsenoside Rk3 and Rh4 (KG-KH) recovers the activity of renal antioxidant
enzymes in cisplatin-injected rats. Acute kidney injury was induced by single injection
of cisplatin (5.0 mg/kg, i.p.). Rats were given KG-KH (0 mg/kg, 2 mg/kg, and 6 mg/kg,
per os) once a day for 5 d from the day of cisplatin injection. Six days after cisplatin
injection, kidney levels of (A) superoxide dismutase (SOD) and (B) catalase (CAT) ac-
tivity were determined in kidney homogenate. Bar represents mean  standard error
of the mean (n ¼ 6). Signiﬁcant differences were determined by the Student t test
(#p < 0.05, ##p < 0.01 compared with normal rats) and ANOVA (*p < 0.05, **p < 0.01
compared with cisplatin control rats). C, cisplatin control rats; N, normal cells.
Please cite this article in press as: Baek S-H, et al., Protective effect of ginse
and in vivo, Journal of Ginseng Research (2016), http://dx.doi.org/10.10163.4. KG-KH restores cisplatin-induced loss of antioxidant enzyme
activity in LLC-PK1 cells (activity of SOD and GR)
We examined the effect of KG-KH on the cellular SOD activity,
which detoxiﬁes superoxide anion. To test the function of the
cellular GSH recycling system, we also examined the cellular GR
activity, which reduces glutathione disulﬁde to GSH. After incuba-
tionwith cisplatin (20mM) or KG-KH (50 mg/mL) in LLC-PK1 cells for
24 h, the cellular activity of SOD and GR was measured. Cisplatin
induced a signiﬁcant decrease of SOD (p < 0.01) and GR activity
(p< 0.001) as compared to normal cells (Figs. 4A and 4B). However,
KG-KH signiﬁcantly recovered the SOD (p < 0.05) and GR activity
(p < 0.05) as compared to cisplatin control cells, suggesting that
KG-KH restored the cisplatin-induced alteration of antioxidant
enzyme activity.3.5. KG-KH restores kidney function in cisplatin-induced AKI in rats
Protective effect of KG-KH on the kidney as a whole was
assessed using an animal model of cisplatin-induced AKI. AKI was
induced by a single intraperitoneal injection of cisplatin (5.0mg/kg)
to male SpragueeDawley rats. KG-KH or saline (control group) was
given to cisplatin-treated rats (2 mg/kg or 6 mg/kg, per os) once a
day for 5 d starting the day of cisplatin injection. Administered dose
of KG-KH did not elicit any noticeable change in the gain of body
weight, behavioral disorders, or organ toxicity in the acute toxicity
test (data not shown). The effects of KG-KH on body weight, kidney
weight, BUN, and creatinine in cisplatin-injected rats are summa-
rized in Table 1. Loss of body weight, a common side effect of
chemotherapeutics, was found in all groups treated with cisplatin
and/or KG-KH. KG-KH failed to recover the gain of body weight.
Cisplatin signiﬁcantly increased kidney index, BUN, and creatinine
as compared to the normal rats (p < 0.01). These data suggest that
cisplatin induced AKI and nephrotoxicity including kidney edema
due to acute inﬂammation, reduction in interstitial ﬂuid, or
impairment of glomerular ﬁltration [33]. KG-KH signiﬁcantly
attenuated cisplatin-induced increase of kidney index, BUN, and
creatinine as compared to cisplatin control rats (p < 0.01), indi-
cating that KG-KH ameliorated cisplatin-induced AKI and recovered
kidney function.3.6. KG-KH restores the kidney level of antioxidant enzyme activity
in cisplatin-induced AKI in rats (SOD and CAT activity)
To examine the effect of KG-KH on oxidative injury in kidney, we
determined activity of antioxidant enzymes in the kidney including
SOD and CAT. Cisplatin signiﬁcantly reduced renal SOD (83.8% of
normal group, p < 0.05) and CAT activity (53.1% of normal group,
p < 0.01) as compared to normal rats (Fig. 5). As expected, KG-KH
signiﬁcantly recovered the renal SOD (96.4% of normal group atnosides Rk3 and Rh4 on cisplatin-induced acute kidney injury in vitro
/j.jgr.2016.03.008
J Ginseng Res 2016;-:1e766 mg/kg, p< 0.01) and CAT activity (85.5% of normal group at 6 mg/
kg, p < 0.01) in a dose-dependent manner.3.7. KG-KH improves renal histology in cisplatin-induced AKI in rats
Histopathological study was carried out using hematoxyline
eosin staining of parafﬁn-embedded kidney sections. Tissue injury
was evaluated in the cortex and outer region of themedulla, a region
rich in proximal tubules [34]. Representative kidney section images
of normal, cisplatin control, and cisplatin with KG-KH groups are
shown in Fig. 6A. In normal rats, kidney exhibited normal architec-
ture with clear glomerulus, distal tubules, and proximal tubules in
cortex and many ducts in the corticomedullary region (Fig. 6A).
Cisplatin increased renal tissue alteration, such as cell death with
dilation of tubules and ducts, exfoliation, shallowing, inﬁltration, and
cast formation. Semiquantitative tissue injury score in both regions
was signiﬁcantly higher in cisplatin control than in normal rats
(p < 0.001; Figs. 6B and 6C). However, KG-KH improved renal his-
tology of both cortex and corticomedullary region in cisplatin-
injected rats and signiﬁcantly ameliorated cisplatin-induced renal
tissue damage (Figs. 6B and 6C). Thus, KG-KH reduced renal cell
death and tissue alteration, thereby contributing to the restoration of
renal function from the cisplatin-induced AKI.Fig. 6. Ginsenoside Rk3 and Rh4 (KG-KH) improves renal histology in cisplatin-injected rats.
6 after cisplatin injection with/without KG-KH were presented. Black arrow indicates tissue
represents 100 mm. Tissue injury in the (B) cortex and (C) corticomedullary regions were ev
sum of all scores. Bar represents mean  standard error of the mean (n ¼ 6). Signiﬁcant differ
or analysis of variance (**p < 0.01 compared with cisplatin control rats). C, cisplatin contro
Please cite this article in press as: Baek S-H, et al., Protective effect of ginse
and in vivo, Journal of Ginseng Research (2016), http://dx.doi.org/10.10164. Discussion
The major ﬁnding of our study was that ginsenosides Rk3 and
Rh4 protected renal tubular cells and restored kidney function from
cisplatin-induced toxicity in in vitro and in vivo. We demonstrated
that oxidative injury is involved in cisplatin-induced AKI and sug-
gested ginsenosides Rk3 and Rh4 as a potential antioxidant through
alleviating cisplatin-induced oxidative injury. Histological results
also supported that ginsenosides Rk3 and Rh4 reduced renal cell
death and tissue alteration, and protected kidney from cisplatin-
induced AKI.
KG-KH protected renal tubular cells and restored kidney func-
tion from cisplatin toxicity through reduction of oxidative injury.
Cisplatin-induced oxidative injury is considered to be the primary
mediator of cisplatin toxicity and orchestrates the subsequent
pathologic events leading to tissue damage and failure of the kid-
ney [13,14]. Many antioxidant phytochemicals, including quercetin
and narigenin, have been studied for the ability to reduce cisplatin
nephrotoxicity through protection against oxidative injury [3,35].
These antioxidants have structural features such as phenolic or
polyphenolic groups responsible for the strong radical-scavenging
activity. Because of the absence of these functional groups, the
antioxidant effect of ginsenosides Rk3 and Rh4 in reducing
cisplatin-induced oxidative injury is predicted to be by an(A) Representative images of the renal pathology (hematoxylineeosin staining) on Day
injury with cell death, inﬁltration, cast formation, exfoliation and shallowing. Scale bar
aluated by semiquantitative scoring of each pathological marker and expressed as the
ences were determined by the Student t test (###p < 0.001 compared with normal rats)
l rats; dt, distal tubule; g, glomerulus; N, normal rats; pt, proximal tubule.
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intrinsic antioxidant enzymes or protection of cellular organelles
such as mitochondria rather than by the direct scavenging of rad-
icals. KG-KH improved antioxidant defense enzyme (CAT, GR, SOD)
activities inactivated by cisplatin. Because these enzymes play
pivotal roles in the metabolism of ROS and recycling of GSH, anti-
oxidant effect of KG-KH might contribute to reduce the cellular
burden of cisplatin-mediated oxidative injury.
Several other ginseng saponins have been studied for recovering
antioxidant enzyme activity in many models of different types of
oxidative stress-mediated diseases. Ginsenosides Rg1 and Re,
which are the precursors of Rk3 and Rh4, exhibit protective effects
against ischemic brain injury, glutamate-induced lung injury, ROS-
induced astrocyte injury, as well as complement-induced podocyte
injury through restoration of the antioxidant defense enzyme ac-
tivities or inhibition of ROS generation [36e39]. Ginsenosides Rg3,
Rg5, and Rk1 reduced cisplatin-induced toxicity through inactiva-
tion of JNK and p53 [40]. Despite the structural differences in many
ginsenosides, ginsenosides exert diverse protective effects onmany
disease models. Their molecular targets or cellular metabolism
should be further studied to understand the bioactivity of indi-
vidual ginsenoside or ginseng extract.
In conclusion, we have demonstrated that ginsenosides Rk3 and
Rh4 alleviate cisplatin cytotoxicity in renal tubular cells and restore
kidney function in a rat model of cisplatin-induced AKI. Antioxidant
strategies that inhibit ROS generation and recover antioxidant de-
fense enzymes are suggested to be the underlying mechanism of
renal protection. Ginsenosides Rk3 and Rh4 could be viable ther-
apeutic agents or adjuvants that reduce nephrotoxicity during
cisplatin chemotherapy.
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